"What" Series

What Is a Blockbuster Drug?

22 March 2024
2 min read

A "blockbuster drug" is a term used in the pharmaceutical industry to describe a medication that is extremely successful in the market, generating significant sales and revenue. Typically, a blockbuster drug is prescribed to a large number of patients and treats a widespread health condition, which contributes to its high sales volume.

Here are some key characteristics of a blockbuster drug:

1.High Demand: The drug addresses a common medical condition or disease, such as high cholesterol, hypertension, or type 2 diabetes, which affects a large patient population.

2.Significant Sales: Blockbuster drugs usually generate annual sales of over a billion dollars, with some even reaching several billions in revenue.

3.Market Leadership: These drugs often dominate their respective therapeutic categories and may set industry standards for treatment.

4.Patent Protection: Blockbusters are typically protected by patents, which prevent generic competition and allow the manufacturer to maintain high prices and profits.

5.Innovation: Blockbuster drugs often represent significant advancements in medical treatment, offering improved efficacy, fewer side effects, or greater convenience compared to existing treatments.

6.Brand Recognition: They are widely recognized by both healthcare professionals and the general public, often due to extensive marketing campaigns.

7.Longevity: While the term originally referred to drugs that became best-sellers within a short time after their release, many blockbuster drugs maintain their sales status for years, even decades, due to ongoing demand and the absence of equally effective alternatives.

Examples of blockbuster drugs include Lipitor (for cholesterol management), Viagra (for erectile dysfunction), and Humira (for various autoimmune conditions). These drugs have not only revolutionized treatment for their respective conditions but have also generated substantial profits for the pharmaceutical companies that developed them.

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Intellia Launches Phase 3 MAGNITUDE Trial for CRISPR Therapy NTLA-2001 in Cardiac Amyloidosis
Latest Hotspot
3 min read
Intellia Launches Phase 3 MAGNITUDE Trial for CRISPR Therapy NTLA-2001 in Cardiac Amyloidosis
22 March 2024
Intellia Therapeutics has revealed the initiation of their Phase 3 clinical trial named MAGNITUDE, where the first participant received a one-time CRISPR therapy, NTLA-2001, aimed at treating cardiac amyloidosis caused by transthyretin.
Read →
Your Ultimate Guide to Finding Glutathione on Synapse
Drug Insights
2 min read
Your Ultimate Guide to Finding Glutathione on Synapse
22 March 2024
Glutathione, a diminutive molecule drug, is a versatile medication used to treat a diverse range of medical conditions.
Read →
Brenig Therapeutics Presents New LRRK2 Inhibitor Findings for Parkinson's Disease at 2024 ACS Spring Meeting
Latest Hotspot
3 min read
Brenig Therapeutics Presents New LRRK2 Inhibitor Findings for Parkinson's Disease at 2024 ACS Spring Meeting
22 March 2024
During the 2024 ACS Spring Meeting, Brenig Therapeutics showcased novel findings related to their leading LRRK2 inhibitor, which is aimed at tackling Parkinson's disease.
Read →
Eli Lilly Reveals the Crystal Form Patent of FGFR3, Unveiling the Structure of LOXO-435
Hot Spotlight
6 min read
Eli Lilly Reveals the Crystal Form Patent of FGFR3, Unveiling the Structure of LOXO-435
21 March 2024
On March 14, 2024, Eli Lilly unveiled a WO patent for a crystalline salt form of an FGFR3 inhibitor, likely relating to LOXO-435's structure, within the pyrimido[4,5-b]pyrazine compound class.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.